Skip to content

Study · Non-randomized trial · n = 31 · 2000

13 results

Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.

Fernholm R, Bramnert M, Hägg E, Hilding A, Baylink DJ, Mohan S, Thorén M

The Journal of clinical endocrinology and metabolism1 Nov 2000Cited by 68 (Europe PMC)

PMID11095440 (opens in a new tab)DOI10.1210/jcem.85.11.6949 (opens in a new tab)PepBankPUB-11095440
Source linkPubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In elderly GH-deficient patients, GH normalized serum IGF-I in most patients.

    In plain wordsIn elderly GH-deficient patients, GH normalized IGF-I in most patients.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGF-I normalization
    Study

    n = 31

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.05 IU/kg x week for 1 month, then 0.1 IU/kg x week divided daily · subcutaneous · 6 months randomized to GH or placebo, followed by 12 months of open treatmentAs given in this study (human).

    Source sentences

    Summary
    GH treatment normalized serum IGF-I in a majority of the patients and increased IGFBP-3 and -5 as well as IGFBP-4 and IGF-II to values within normal range.
    2 context sentences
    Summary · context
    They were randomized to GH (Humatrope, Eli Lilly & Co.) or placebo for 6 months, followed by 12 months of open treatment.
    Summary · context
    The dose was 0.05 IU/kg x week for 1 month, and after that it was 0.1 IU/kg x week divided into daily sc injections (0.75-1.25 IU/day).
  2. 02HumanNon-randomized trialEfficacy outcome

    In elderly GH-deficient patients, GH increased IGFBP-3 into the normal range.

    In plain wordsIn elderly GH-deficient patients, GH increased IGFBP-3 into the normal range.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGFBP-3
    Study

    n = 31

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.05 IU/kg x week for 1 month, then 0.1 IU/kg x week divided daily · subcutaneous · 6 months randomized to GH or placebo, followed by 12 months of open treatmentAs given in this study (human).

    Source sentences

    Summary
    GH treatment normalized serum IGF-I in a majority of the patients and increased IGFBP-3 and -5 as well as IGFBP-4 and IGF-II to values within normal range.
    2 context sentences
    Summary · context
    They were randomized to GH (Humatrope, Eli Lilly & Co.) or placebo for 6 months, followed by 12 months of open treatment.
    Summary · context
    The dose was 0.05 IU/kg x week for 1 month, and after that it was 0.1 IU/kg x week divided into daily sc injections (0.75-1.25 IU/day).
  3. 03HumanNon-randomized trialEfficacy outcome

    In elderly GH-deficient patients, GH increased IGFBP-5 into the normal range.

    In plain wordsIn elderly GH-deficient patients, GH increased IGFBP-5 into the normal range.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGFBP-5
    Study

    n = 31

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.05 IU/kg x week for 1 month, then 0.1 IU/kg x week divided daily · subcutaneous · 6 months randomized to GH or placebo, followed by 12 months of open treatmentAs given in this study (human).

    Source sentences

    Summary
    GH treatment normalized serum IGF-I in a majority of the patients and increased IGFBP-3 and -5 as well as IGFBP-4 and IGF-II to values within normal range.
    2 context sentences
    Summary · context
    They were randomized to GH (Humatrope, Eli Lilly & Co.) or placebo for 6 months, followed by 12 months of open treatment.
    Summary · context
    The dose was 0.05 IU/kg x week for 1 month, and after that it was 0.1 IU/kg x week divided into daily sc injections (0.75-1.25 IU/day).
  4. 04HumanNon-randomized trialEfficacy outcome

    In elderly GH-deficient patients, GH increased IGFBP-4 into the normal range.

    In plain wordsIn elderly GH-deficient patients, GH increased IGFBP-4 into the normal range.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGFBP-4
    Study

    n = 31

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.05 IU/kg x week for 1 month, then 0.1 IU/kg x week divided daily · subcutaneous · 6 months randomized to GH or placebo, followed by 12 months of open treatmentAs given in this study (human).

    Source sentences

    Summary
    GH treatment normalized serum IGF-I in a majority of the patients and increased IGFBP-3 and -5 as well as IGFBP-4 and IGF-II to values within normal range.
    2 context sentences
    Summary · context
    They were randomized to GH (Humatrope, Eli Lilly & Co.) or placebo for 6 months, followed by 12 months of open treatment.
    Summary · context
    The dose was 0.05 IU/kg x week for 1 month, and after that it was 0.1 IU/kg x week divided into daily sc injections (0.75-1.25 IU/day).
  5. 05HumanNon-randomized trialEfficacy outcome

    In elderly GH-deficient patients, GH increased IGF-II into the normal range.

    In plain wordsIn elderly GH-deficient patients, GH increased IGF-II into the normal range.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGF-II
    Study

    n = 31

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.05 IU/kg x week for 1 month, then 0.1 IU/kg x week divided daily · subcutaneous · 6 months randomized to GH or placebo, followed by 12 months of open treatmentAs given in this study (human).

    Source sentences

    Summary
    GH treatment normalized serum IGF-I in a majority of the patients and increased IGFBP-3 and -5 as well as IGFBP-4 and IGF-II to values within normal range.
    2 context sentences
    Summary · context
    They were randomized to GH (Humatrope, Eli Lilly & Co.) or placebo for 6 months, followed by 12 months of open treatment.
    Summary · context
    The dose was 0.05 IU/kg x week for 1 month, and after that it was 0.1 IU/kg x week divided into daily sc injections (0.75-1.25 IU/day).
  6. 06HumanNon-randomized trialEfficacy outcome

    In elderly GH-deficient patients, GH modestly but highly significantly reduced total body fat.

    In plain wordsIn elderly GH-deficient patients, GH reduced total body fat.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseTotal body fat
    Study

    n = 31

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    0.05 IU/kg x week for 1 month, then 0.1 IU/kg x week divided daily · subcutaneous · 6 months randomized to GH or placebo, followed by 12 months of open treatmentAs given in this study (human).

    Source sentences

    Summary
    GH treatment caused a modest, but highly significant, reduction of total body fat.
    2 context sentences
    Summary · context
    They were randomized to GH (Humatrope, Eli Lilly & Co.) or placebo for 6 months, followed by 12 months of open treatment.
    Summary · context
    The dose was 0.05 IU/kg x week for 1 month, and after that it was 0.1 IU/kg x week divided into daily sc injections (0.75-1.25 IU/day).
  7. 07HumanNon-randomized trialEfficacy outcome

    In elderly GH-deficient patients, bone mineral density did not change during GH treatment.

    In plain wordsIn elderly GH-deficient patients, bone mineral density did not change during GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeBone mineral density
    Study

    n = 31

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.05 IU/kg x week for 1 month, then 0.1 IU/kg x week divided daily · subcutaneous · 6 months randomized to GH or placebo, followed by 12 months of open treatmentAs given in this study (human).

    Source sentences

    Summary
    Mean bone mineral density was not different from that in healthy subjects of the same age and did not change during the observation period.
    2 context sentences
    Summary · context
    They were randomized to GH (Humatrope, Eli Lilly & Co.) or placebo for 6 months, followed by 12 months of open treatment.
    Summary · context
    The dose was 0.05 IU/kg x week for 1 month, and after that it was 0.1 IU/kg x week divided into daily sc injections (0.75-1.25 IU/day).
  8. 08HumanNon-randomized trialEfficacy outcome

    In elderly GH-deficient patients, bone-specific alkaline phosphatase increased within the normal range and remained elevated during GH treatment.

    In plain wordsIn elderly GH-deficient patients, GH increased bone-specific alkaline phosphatase within the normal range.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseBone-specific alkaline phosphatase
    Study

    n = 31

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.05 IU/kg x week for 1 month, then 0.1 IU/kg x week divided daily · subcutaneous · 6 months randomized to GH or placebo, followed by 12 months of open treatmentAs given in this study (human).

    Source sentences

    Summary
    Markers for bone formation (bone-specific alkaline phosphatase activity, osteocalcin, and procollagen I carboxyl-terminal peptide in serum) increased within the normal range, and levels were sustained throughout the study.
    2 context sentences
    Summary · context
    They were randomized to GH (Humatrope, Eli Lilly & Co.) or placebo for 6 months, followed by 12 months of open treatment.
    Summary · context
    The dose was 0.05 IU/kg x week for 1 month, and after that it was 0.1 IU/kg x week divided into daily sc injections (0.75-1.25 IU/day).
  9. 09HumanNon-randomized trialEfficacy outcome

    In elderly GH-deficient patients, osteocalcin increased within the normal range and remained elevated during GH treatment.

    In plain wordsIn elderly GH-deficient patients, GH increased osteocalcin within the normal range.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseOsteocalcin
    Study

    n = 31

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.05 IU/kg x week for 1 month, then 0.1 IU/kg x week divided daily · subcutaneous · 6 months randomized to GH or placebo, followed by 12 months of open treatmentAs given in this study (human).

    Source sentences

    Summary
    Markers for bone formation (bone-specific alkaline phosphatase activity, osteocalcin, and procollagen I carboxyl-terminal peptide in serum) increased within the normal range, and levels were sustained throughout the study.
    2 context sentences
    Summary · context
    They were randomized to GH (Humatrope, Eli Lilly & Co.) or placebo for 6 months, followed by 12 months of open treatment.
    Summary · context
    The dose was 0.05 IU/kg x week for 1 month, and after that it was 0.1 IU/kg x week divided into daily sc injections (0.75-1.25 IU/day).
  10. 10HumanNon-randomized trialEfficacy outcome

    In elderly GH-deficient patients, procollagen I carboxyl-terminal peptide increased within the normal range and remained elevated during GH treatment.

    In plain wordsIn elderly GH-deficient patients, GH increased procollagen I carboxyl-terminal peptide within the normal range.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseProcollagen I carboxyl-terminal peptide
    Study

    n = 31

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.05 IU/kg x week for 1 month, then 0.1 IU/kg x week divided daily · subcutaneous · 6 months randomized to GH or placebo, followed by 12 months of open treatmentAs given in this study (human).

    Source sentences

    Summary
    Markers for bone formation (bone-specific alkaline phosphatase activity, osteocalcin, and procollagen I carboxyl-terminal peptide in serum) increased within the normal range, and levels were sustained throughout the study.
    2 context sentences
    Summary · context
    They were randomized to GH (Humatrope, Eli Lilly & Co.) or placebo for 6 months, followed by 12 months of open treatment.
    Summary · context
    The dose was 0.05 IU/kg x week for 1 month, and after that it was 0.1 IU/kg x week divided into daily sc injections (0.75-1.25 IU/day).
  11. 11HumanNon-randomized trialEfficacy outcome

    In elderly GH-deficient patients, urinary pyridinoline was significantly elevated for 12 months during GH treatment.

    In plain wordsIn elderly GH-deficient patients, urinary pyridinoline increased during GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseUrinary pyridinoline
    Study

    n = 31

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.05 IU/kg x week for 1 month, then 0.1 IU/kg x week divided daily · subcutaneous · 6 months randomized to GH or placebo, followed by 12 months of open treatmentAs given in this study (human).

    Source sentences

    Summary
    The bone resorption marker (pyridinoline in urine) was significantly elevated for 12 months.
    2 context sentences
    Summary · context
    They were randomized to GH (Humatrope, Eli Lilly & Co.) or placebo for 6 months, followed by 12 months of open treatment.
    Summary · context
    The dose was 0.05 IU/kg x week for 1 month, and after that it was 0.1 IU/kg x week divided into daily sc injections (0.75-1.25 IU/day).
  12. 12HumanNon-randomized trialSafety outcome

    In elderly GH-deficient patients, GH side effects were mild and mostly attributed to fluid retention.

    In plain wordsIn elderly GH-deficient patients, GH side effects were mild and mostly linked to fluid retention.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableMild fluid-retention side effects
    Study

    n = 31

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.05 IU/kg x week for 1 month, then 0.1 IU/kg x week divided daily · subcutaneous · 6 months randomized to GH or placebo, followed by 12 months of open treatmentAs given in this study (human).

    Source sentences

    Summary
    Side-effects were mild, mostly attributed to fluid retention.
    2 context sentences
    Summary · context
    They were randomized to GH (Humatrope, Eli Lilly & Co.) or placebo for 6 months, followed by 12 months of open treatment.
    Summary · context
    The dose was 0.05 IU/kg x week for 1 month, and after that it was 0.1 IU/kg x week divided into daily sc injections (0.75-1.25 IU/day).
  13. 13HumanObservational studyEfficacy outcome

    In elderly GH-deficient patients, lean mass increased and correlated with IGF-I increases at 6 months (r = 0.46, P = 0.010) and 12 months (r = 0.54, P = 0.003).

    In plain wordsIn elderly GH-deficient patients, GH increased lean body mass, with increases linked to IGF-I increases.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLean body mass
    Study

    n = 31

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    0.05 IU/kg x week for 1 month, then 0.1 IU/kg x week divided daily · subcutaneous · 6 months randomized to GH or placebo, followed by 12 months of open treatmentAs given in this study (human).

    Measurements

    Correlation of lean body mass increase with IGF-I increase (r)
    0.46 r
    6 months
    P value for correlation
    0.01 P
    6 months
    Correlation of lean body mass increase with IGF-I increase (r)
    0.54 r
    12 months
    P value for correlation
    0.003 P
    12 months

    Source sentences

    Summary
    Lean body mass was increased, and the increase at 6 and 12 months correlated with the increase in IGF-I (r = 0.46; P = 0.010 and r = 0.54, respectively; P = 0.003).
    2 context sentences
    Summary · context
    They were randomized to GH (Humatrope, Eli Lilly & Co.) or placebo for 6 months, followed by 12 months of open treatment.
    Summary · context
    The dose was 0.05 IU/kg x week for 1 month, and after that it was 0.1 IU/kg x week divided into daily sc injections (0.75-1.25 IU/day).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.